EGFR and non-small cell lung carcinoma: [14] Rosell R, Gervais A, Vergrenegre B, Massati E, Felip F, et al.  Erlotinib versus chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib versus Chemotherapy (EURTAC) Phase III randomized trial.